DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
De Placido S, Gallo C, De Laurentiis M. et al.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2
years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a
randomised, phase 3 trial.
Lancet Oncol 2018;
19: 474-485
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.